

Cumulative Index 1990

Volume 11

| | |
|------------------|---|
| March | DRUG-INDUCED PULMONARY DISEASE, pages 1-194 |
| June | PULMONARY CONSIDERATIONS IN TRANSPLANTATION, pages 195-362 |
| September | CHRONIC OBSTRUCTIVE PULMONARY DISEASE, pages 363-573 |
| December | ADULT RESPIRATORY DISTRESS SYNDROME, pages 575-811 |

Note: Page numbers of complete issue and article titles are in **boldface type**.

Accelerated (cellular) rejection, definition, 270-271
ACE inhibitors. See *Angiotensin-converting enzyme inhibitors*.

Acetylcysteine, for COPD, 473

Acinus, lesions in, 395-400

Acupuncture, for dyspnea in COPD, 436

Acute chest pain syndrome, bleomycin-induced, 17

Acute lung injury, alveolar fibrosis following, mechanisms, 657-672

anatomy, 659-662

in ARDS, 634

pneumonia and, 644

definition, 657

fibroproliferative response in, 659-665

scoring system, 575-576

β -Adrenergic agents, for cor pulmonale in COPD, 530-532

α -Adrenergic blockers, for cor pulmonale in COPD, 536-537

β -Adrenoceptor agonists. See also *β -Sympathomimetics*.
for COPD, 465-469

theophylline and, for COPD, 467-468

Adult respiratory distress syndrome (ARDS), clinical disorders associated with, 576-579

clinicopathologic correlations, 616

cytokines in, 624-626

death in, causes, 578, 581

definition, 575-580

endothelial injury in, 596-598

fibrosis in, 601-604

gas exchange abnormalities, 587

heart-lung interaction, 691-714

histologic changes, 797

issue on, 575-800

long-term sequelae, radiographic assessment, 744-745

lung mechanics, 673-690

altered, implications, 684-687

compliance, 676-678

functional residual capacity, 684

mean airway pressure, 680

mean alveolar pressure, 680

measurement of, in pressure-controlled ventilation, 684

monitoring of, 681-684

resistance, 678-680

lung mechanics in, peak cycling pressure, 680-681

lung metabolic function in, 723-736

functional significance, 732-733

future directions, 730-732

macrophages in, 624

management, ventilatory, 755-772

conventional methods, 755-759

unconventional methods, 759-769

mechanisms, 621-632

multiple organ failure in, prevention, 639-641

neutrophils in, 621-622, 627-628

nosocomial pneumonia in, 641-656. See also *Pneumonia, nosocomial*.

organ failure in, multiple, 581-591. See also *Multiple organ failure, in ARDS*.

nonpulmonary, 579

oxygen supply and consumption in, 715-722

oxygen uptake-oxygen delivery relationships, 585

pathoanatomy, 675-681

pathogenesis, endotoxin in, 622-624

following septic syndrome, 636-637

PEEP in, 695-697

postmortem arteriographic patterns, 608

prognosis, 575-580

pulmonary endothelial cell injury in, 723-736

pulmonary pathology, 593-619

experimental models, 613-616

exudative phase, 593-598

fibrotic phase, 605

localization of lesions, 612-613

proliferative phase, 599-605

pulmonary vasculature in, 606-612

radiographic assessment, 737-754

sepsis in, 576-579, 633-641. See also *Sepsis*.

stages, radiographic assessment, 737-743

survivors of, airflow resistance in, 792-793

clinical evaluation, 790-791, 797-798

- Adult respiratory distress syndrome (ARDS) (*Continued*)
laboratory studies, 791-792
lung mechanics in, 792-793
lung volume measurement in, 793-794
pulmonary sequelae, 789-800
respiratory symptoms in, 790-791
treatment, pharmacologic, 773-787
ventricular function, 705-709
- Afterload, left ventricular, 702
right ventricular, 694-698
- Age, as factor in bleomycin-induced pulmonary toxicity, 2
as factor in COPD, 377
as factor in lung transplantation, 212
as factor in pulmonary sequelae following ARDS, 795
- Aging, panacinar emphysema associated with, 398
- β -Agonists, for COPD, 366
- Air-lung interface, anatomy, 658
granulation of air space, 663-667
- Air pollution, as factor in COPD, 383
- Air space, granulation of, 663-667
- Air space enlargement, classification, 396-397
emphysema and, 395-396
and fibrosis, 398-399
- Airflow resistance, in ARDS survivors, 792-793
- Airway, anatomy and physiology, 163-166
complications affecting, following lung transplantation,
radiologic assessment, 341-343
- Airway disease, following bone marrow transplantation,
329
- Airway obstruction, chronic, and bronchiolitis, 392-395
lesions occurring with, 389-390
in COPD, 363
- Airway pressure, in ARDS, monitoring of, 682-683
positive, as factor in pulmonary sequelae following
ARDS, 796
- Alcohol, as cause of hiccups, 184
as cause of respiratory depression, 178-179
in COPD, 383
- Alkylating agents, pulmonary toxicity, 31-36
- Allograft recipients, lung, infectious complications in,
291-308
bacterial pneumonia, 292-294
CMV infection, 295-299
mediastinitis, 294-295
Pneumocystis carinii infection, 299-301
- Allograft rejection, following lung transplantation, radio-
logic assessment, 336-339
- lung, 269-278
chronic, and infection, 303-306
clinical definition, 270-272
in COPD patients, 553
Epstein-Barr virus and, 303
functional correlated, 273
histologic evidence, 272-273
immunologic parameters, 273-275
immunopathogenesis, 269-270
management, 275-276
signs of, 266
soluble IL-2R in, 274-275
- Almitrine, for COPD, 475
for cor pulmonale in COPD, 537-539
- Alpha-adrenergic blockers. See α -Adrenergic blockers.
- Alpha-antitrypsins. See α_1 -Antitrypsins.
- Alprazolam, for dyspnea in COPD, 431
- Alveolar anatomy, 658-659
- Aminoglycosides, for pneumonia in ARDS, 649
- Amiodarone, as cause of lung injury, histopathology, 113-
114
pharmacokinetics and metabolism of, relation to toxic-
ity, 131-132
- toxicity of, pulmonary, clinical aspects, 119-129
clinical manifestations, 120-122
diagnostic evaluation, 123-125
bronchoalveolar lavage, 123-124
diagnostic evaluation of, gallium scintigraphy, 123
direct, evidence for, 132-135
indirect, evidence for, 135-136
mechanisms, 131-138
pathology, 124
peripheral blood findings, 122
physical findings, 122
prognosis of patients with, 125-126
pulmonary function testing, 122-123
roentgenographic abnormalities, 122
treatment, 126-127
- Angiotensin-converting enzyme (ACE) inhibitors, as cause
of bronchospasm, 169-170
- Anti-inflammatory agents, for COPD, 367
in prevention of ARDS and multiple organ failure, 639-
640
- Antibiotics, for COPD, 473-474
for pneumonia in ARDS, 649
pulmonary toxicity, 40-43
- Antibodies, preformed, in prevention of sepsis, 651
- Anticholinergics, for COPD, 367, 469-471
for emphysema, 367
- Anticoagulation, in early postoperative management fol-
lowing lung transplantation, 265
- Antidepressants, for COPD, 478-479
- Antidopamine, in prevention of ARDS and multiple or-
gan failure, 640-641
- Antidotoxin antibodies, for ARDS, 780-781
- Antidotoxins, in prevention of ARDS and multiple or-
gan failure, 639
- Antimetabolites, pulmonary toxicity, 36-40
- Antimicrobial agents, in early postoperative management
following lung transplantation, 262-263
for pneumonia in ARDS, 649
- Antirheumatic agents, as cause of pulmonary disease,
139-150
- α_1 -Antitrypsins, in COPD, 476
- Antitumor necrosis factor antibodies, for ARDS, 782-783
- Antitussives, for COPD, 476-477
- Anxiolytics, for COPD, 478
- Arachidonic acid, role in bleomycin-induced lung fibrosis,
23-24
- ARDS. See *Adult respiratory distress syndrome*.
- Arterial blood gases, in long-term functional follow-up of
lung transplant recipients, 351-352
- Arthritis, rheumatoid, bronchiolitis and, penicillamine as
cause of, 111
drug-induced, 110-113
gold salt-induced, 112-113
- Aspergillosis, in the immunocompromised host, 60-61
- Aspergillus, as cause of fungal infections in lung transplant
recipients, 302
as cause of infection following bone marrow transplan-
tation, 325
- Aspirin, as cause of bronchospasm, 167-169
- Asthma, cromolyn for, 367
definition, 363-364
diagnosis, 405-416
pulmonary function testing, 407-410, 414-415
- Atelectasis, drug abuse as cause of, 155
- Atopy, as factor in COPD, 383-384
- Atropine, for COPD, 470
- Azathioprine, in management of lung allograft rejection,
275
in management of lung transplant recipients, 280

- pulmonary toxicity, 39-40
 Aztreonam, for pneumonia in ARDS, 649
- Barotrauma, in ARDS, prevention, 686-687
 radiographic assessment, 747-748
- Beta-agonists. See β -Agonists.
- Beta-sympathomimetics. See β_2 -Sympathomimetics.
- Bleomycin, as cause of acute chest pain syndrome, 17
 as cause of hypersensitivity pneumonitis, 16-17
 as cause of interstitial fibrosis, 2-14
 mechanisms, 21-30
 as cause of lung injury, 98-99
 histopathology, 99
 collagen synthesis following, 21-22
 effect on pulmonary function tests, 14-16
 routes of administration, 1
 toxicity of, effects on organ systems, 1
 pulmonary, 1-20, 69. See also *Pulmonary toxicity, bleomycin-induced*.
- β -Blockers, as cause of bronchospasm, 166-167
- Blood-lung interface, anatomy, 659, 661-662
 following acute lung injury, 667-668
- Bone marrow transplantation, immunosuppressive agents used in, 321-322
 pulmonary complications following, 321-332
 acute, 324-327
 chronic, 327-329
 diagnostic approach, 329-330
 pulmonary complications in, 58
 survival statistics, 324
- Borg category scale, 438
- Breathlessness. See *Dyspnea*.
- Bronchi, lesions of, 390-391
- Bronchiectasis, heroin abuse as cause of, 156
- Bronchiolitis, chronic airway obstruction and, 392-395
 obliterative, following heart-lung transplantation, 309-321
 clinical manifestations, 310-315
 definition, 309-310
 etiology, 317-318
 pathogenesis, 318-320
 prognosis, 317
 pulmonary function alterations, 313
 treatment, 315-317
 respiratory, 395
- Bronchiolitis obliterans, following lung transplantation, 339-341
 gold salt-induced, 143-144
 penicillamine-associated, 141-142
 penicillamine-induced, 111-112
- Bronchitis, asthmatic, definition, 364
 chronic, bronchial wall thickening in, 391
 definition, 364
 diagnosis, 405-416
 pulmonary function testing, 407-410
 inflammation in, 391
 mucous gland enlargement in, 390-391
 smooth muscle hyperplasia in, 391
 lymphocytic, following bone marrow transplantation, 327
- Bronchoalveolar lavage, for determining infection following lung transplantation, 271-272, 273-274
 in evaluation of amiodarone pulmonary toxicity, 123-124
- Bronchodilators, for COPD, 425
- Bronchospasm, drug-induced, 163-175
 β -blockers, 166-167
 ACE inhibitors, 169-170
 aspirin, 167-169
 cholinesterase inhibitors, 167
 inhalational agents, 171-172
 neuromuscular blocking agents, 172
- Bruce protocol, modified, in long-term functional follow-up of lung transplant recipients, 356
- Busulfan, pulmonary toxicity, 35-36
 uses, 35
- Calcium channel blockers, as cause of neuromuscular transmission impairment, 180-181
- Candida albicans*, as cause of fungal infections in lung transplant recipients, 301-302
- Candidiasis, in the immunocompromised host, 61
- Cannulas, reservoir, for oxygen delivery, 515
- Captopril, for cor pulmonale in COPD, 537
- Cardiovascular failure, in ARDS, 581-582
- Carmustine, pulmonary toxicity, 45-47
- Catheters, pulmonary infarction caused by, in ARDS, radiographic assessment, 751-752
 transtracheal, for oxygen delivery, 514-515
- Central nervous system (CNS) failure, in ARDS, 583
- Chemotherapeutic agents, and bleomycin, as cause of pulmonary toxicity, 6
- Chest pain, acute, bleomycin-induced, 17
- Chlorambucil, pulmonary toxicity, 36
- Chlorozotocin, pulmonary toxicity, 48
- Cholinesterase inhibitors, as cause of bronchospasm, 164
- Chronic obstructive pulmonary disease (COPD), acute respiratory failure in, oxygen therapy for, 508-509
 age as factor in, 377
 asthma in, 363-364
 bronchitis in, 364
 cor pulmonale in, 523-545. See also *Pulmonary heart disease, in COPD*.
 course and prognosis, 367
 definitions, 363-373
 diagnosis, 405-416. See also specific diagnostic tests.
 disease states leading to, 365-366
 dyspnea in, 417-445
 acupuncture for, 436
 evaluation, 423-425
 emphysema in, 364-365
 epidemiology, 375-387
 ethnic status as factor in, 377-379
 exercise reconditioning in, 433-435
 features, 363
 gender differences in, 376-377
 hyperinflation in diagnosis of, 367-371
 inspiratory muscle training in, 431-433
 issue on, 363-569
 lung transplantation for, 547-554
 medical problems associated with, and dyspnea, 422-423
 morbidity in, 375-379
 mortality in, 379-380
 nutritional assessment and support in, 487-504. See also *Nutrition, in COPD*.
 oxygen for, 429-430
 in the home, long-term, 505-521
 oxygen transport and mixed venous oxygenation in, 525-529
 pathophysiology, 389-403
 and dyspnea, 420-421
 prognosis, 555-569
 comparison of studies, 557-567
 problems related to, 555
 survival curves, 564-567

Chronic obstructive pulmonary disease (COPD)

(Continued)

- survival factors, 556-564
 - psychologic and psychosocial therapy for, 436
 - pulmonary hypertension in, etiology and natural history, 524-525
 - pulmonary rehabilitation in, 447-460, 510-511. See also *Pulmonary rehabilitation, for COPD.*
 - pursed lips breathing in, 433
 - risk factors, 380-384
 - risk models, 384
 - role of cardiac output response in adaptation to, 529
 - single lung transplantation in, 196
 - treatment, 425-436
 - antitussives, 476-477
 - long-term, 479-482
 - oxygen, 474-475
 - pharmacologic, 461-487
 - antibiotics, 473-474
 - anticholinergics, 469-471
 - corticosteroids, 471-472
 - diuretics, 476
 - mucokinetic agents, 472-473
 - psychoactive drugs, 477-479
 - respiratory stimulants, 475
 - sympathomimetics, 465-469
 - theophylline, 461-465
 - systematic, responses, 365-367
 - undernutrition in, magnitude of, 488
 - significance, 487-488
- CMV. See *Cytomegalovirus infection.*
- Cocaine abuse, pulmonary complications caused by, 156-158
- Colchicine, as cause of pulmonary disease, 147
- Collagen, synthesis of, following bleomycin treatment, 21-22
- Companion, for oxygen delivery, 515-516
- Compliance, in left ventricular function, 699-702
- Computed tomography (CT), in drug-induced pulmonary disease, 88-91
 - in emphysema, 412-414
 - in interstitial fibrosis secondary to bleomycin-induced toxicity, 9-11
- Contrast media, as cause of bronchospasm, 170
- COPD. See *Chronic obstructive pulmonary disease.*
- Cor pulmonale. See *Pulmonary heart disease.*
- Corticosteroids, for amiodarone pulmonary toxicity, 127
 - for ARDS, 774-776
 - for COPD, 471-472
- as factor in lung transplantation, 213
- for radiation-induced lung injury, 69-70
- Cough, drug-induced, 163-175
- Cromolyn, for asthma, 367
- for COPD, 475
- Cryptococcus neoformans* infection, in the immunocompromised host, 61
- Cryptococcus neoformans*, as cause of fungal infections in lung transplant recipients, 302
- CT. See *Computed tomography.*
- Cyclophosphamide, pulmonary toxicity of, 31-35
 - and lung injury, 101-102
 - clinical features, 33-34
 - histopathology, 101-102
 - mechanisms, 31-33
 - risk factors, 34
- Cyclosporine, in heart-lung transplantation, 235-236
 - in lung allograft rejection, 275
 - in management of lung transplant recipients, 263, 279-280
 - with cystic fibrosis, 285

- side effects, 280-283
 - gastric atony, 282
 - hepatotoxicity, 281
 - hyperkalemia, 283
 - hypertension, 281
 - hypertrichosis and gingival hyperplasia, 282
 - hypomagnesemia, 282-283
 - nephrotoxicity, 281
 - neurologic manifestations, 282
 - photosensitivity/skin lesions, 283
 - in management of lung transplant recipients with COPD, 551-553
- Cystic fibrosis, lung transplantation recipients with, post-operative management, 284-285
- Cytochrome P₄₅₀ enzymes, role in oxygen toxicity, 76
- Cytokines, in regulation of inflammation, 624-626
- Cytomegalovirus (CMV) infection, following bone marrow transplantation, 325-326, 328
 - following heart-lung transplantation, 243-244
 - following lung transplantation, 263, 295-299
 - clinical manifestations, 297
 - occurrence in postoperative course, 295-296
 - pneumonia from, 297-298
 - prevalence, 296-297
 - prevention, 286-287
 - treatment and outcome, 298-299
 - in the immunocompromised host, 59-60
- Cytosine arabinoside, pulmonary toxicity, 38-39
- Cytotoxic agents, major tissue reactions with, 95-98
 - pulmonary toxicity of, 31-54. See also specific agents, e.g., *Cyclophosphamide.*
- Decontamination, selective, in prevention of pneumonia, 651
- Delayed (cellular) rejection, definition, 271
- Dexamethasone, for ARDS, 775-776
- Diazepam, for dyspnea in COPD, 430-431
- Digitalis, for cor pulmonale in COPD, 529-530
- Digoxin, for COPD, 475-476
- Dihydrocodeine, for dyspnea in COPD, 431
- Diuretics, for COPD, 476
- Donor lung, and early thoracic infections, 219-220
 - preservation techniques, 223-225
 - procurement of, 220-222
- Donors, in lung transplantation. See *Lung transplantation, donors in.*
- for COPD patients, 548
- DO2S system, for oxygen delivery, 516
- Drug abuse, pulmonary reactions, 151-162
 - foreign body granulomatosis, 153-155
 - infectious complications, 151-152
 - pleural abnormalities, 153
 - pneumomediastinum, 152-153
 - pneumothorax, 152-153
 - pulmonary bullae and atelectasis, 155
 - pulmonary hypertension, 153-155
- Drugs, adverse effects of, on respiratory muscles, 177-189
- Dyspnea, in COPD, 417-445
 - treatment, 425-436
 - effect of posture on, 436
 - evaluation, 423-425
 - intermittent negative pressure ventilation for, 436
 - medical problems associated with COPD as cause of, 422-423
 - oxygen for, 429-430
 - pathophysiology of COPD and, 420-421
 - physiologic mechanisms, 417-420
 - hypercapnea, 420
 - hypoxemia, 420

- increase in ventilatory drive, 418-419
 - length-tension inappropriateness, 419
 - pulmonary arterial or venous hypertension, 419-420
 - psychosocial variables related to, 421-422
 - pulmonary function testing, 436
 - pursed lips breathing in, 433
 - surgery for, 436
 - Dyspnea index, baseline, 440-441
 - transition, 442-443
- Edema, hydrostatic versus increased-permeability, in**
- ARDS, radiographic assessment, 745-746
 - pulmonary. *See Pulmonary edema.*
- Emphysema, and airspace enlargement, 395-396**
- anticholinergics for, 367
 - cartilage atrophy in, 391
 - clinical correlations and diagnosis, 399-400
 - definition, 364-365, 395-396
 - diagnosis, 405-416
 - CT in, 412-414
 - hyperinflation in, 367-371
 - pulmonary function testing, 407-410
 - malnourished patients with, 435-436
 - morphology, 397-399
 - single lung transplantation in, 228
 - transplant consideration for patients with, 547-548
- Endothelial cell injury, pulmonary, in ARDS, 723-736**
- von Willebrand factor antigen as indicator of, 724, 725
- Endothelium, injury to, in ARDS, 596-598**
- pulmonary, metabolic activity of, 724-730
- Endotoxin, in ARDS, 622-624**
- Endotracheal intubation, as cause of pneumonia in ARDS, 645**
- Eosinophils, pulmonary, as cause of lung injury, 104-105**
- role in inflammatory process associated with bleomycin-induced lung fibrosis, 27
- Epstein-Barr virus infections, as cause of fungal infections in lung transplant recipients, 302-303**
- Ethchlorvynol abuse, pulmonary complications caused by, 158**
- Ethnic groups, COPD in, 377-379**
- Euro-Collins solution, for pulmonary flush, modified, 221**
- Exercise, following lung transplantation, 252, 254**
- oxygen therapy during, in COPD patients, 509
- Exercise training, in COPD, 433-435**
- Fatigue, drug-induced, 185**
- Fibrosis, airspace enlargement and, 398-399**
- alveolar, following acute lung injury, 657-672
 - in ARDS, 601-604
 - bleomycin-induced, expression of gene products following, 24-25
 - future research, 27
 - inflammatory cell changes in, 25-27
 - mechanisms, 21-30
 - role of arachidonic acid products in, 23-24
 - role of oxygen intermediates/antioxidant systems, 22-23
 - interstitial, bleomycin-induced, 2-14
 - clinical presentation, 8-9
 - course, 13-14
 - diagnosis, 12-13
 - factors influencing, 2-6
 - mortality, 14
 - outcome, 13-14
 - pathology, 6-8
 - radiographic manifestations, 9-12
 - idiopathic, in the immunocompromised host, 61-62
 - risk factors, 4
 - radiation, 68
 - Flush prostaglandin Euro-Collins solution technique, for procurement of donor lungs, 221-225
 - Foreign body granulomatosis, drug abuse as cause of, 153-155
 - Functional residual capacity, in ARDS, 684
 - Fungus(i), in lung allograft recipients, 301-303
- Gallium-67 lung scintigraphy, in evaluation of amiodarone pulmonary toxicity, 123**
- Gallium scans, in pulmonary interstitial fibrosis secondary to bleomycin-induced toxicity, 11-12**
- Ganciclovir, and hyperimmune globulin, for prevention of *Pneumocystis carinii* infection, 287**
- Gastric emptying, side effects, 282**
- Gastrointestinal failure, in ARDS, 582**
- Genes, expression of, following bleomycin-induced lung fibrosis, 24-25**
- Genetics, as factor in COPD, 382-383**
- Gold salts, as cause of pulmonary disease, 142-144**
- as cause of rheumatoid lung, 112-113
- Graft failure, primary, histology, 222-223**
- Guillain-Barré syndrome, respiratory muscle paresis or paralysis in, 179**
- Heart-lung interaction, in ARDS, 691-714**
- Heart-lung transplantation, 235-246**
- allograft rejection following, management, 275-276
 - arterial blood gases following, 351-352
 - for COPD, procedure, 548-549
 - donor selection in, 237
 - history, 235-236
 - immunosuppression following, 242
 - indications, 209-210
 - late results and complications, 244-245
 - obliterative bronchiolitis following, 309-321. *See also Bronchiolitis, obliterative.*
 - organ preservation in, 239-240
 - pulmonary complications following, 242-244
 - implantation response, 242
 - infection, 243-244
 - rejection, 242-243
 - pulmonary function testing following, 273, 350
 - recipient management, 240-244
 - recipient selection, 236-237
 - 6-minute walk test following, 354
 - stage I exercise test following, 356
 - technique, 237-240
 - procurement of donor organs, 237-239
 - removal of diseased heart and lungs and donor organ implantation, 239
- Hematologic failure, in ARDS, 583**
- Hemorrhage, alveolar, following bone marrow transplantation, 326-327**
- following double lung transplantation, re-exploration for, 232
- Heroin abuse, as cause of bronchiectasis, 155**
- as cause of pulmonary edema, 155-156
- Hiccups, drug-induced, 184-185**
- Humoral (hyperacute) rejection, definition, 270**
- Hydralazines, for cor pulmonale in COPD, 534**

- Hydrocarbons, inhalation of, pulmonary complications caused by, 159
- Hypercholesterolemia, following lung transplantation, 285-286
- Hyperimmune globulin, and ganciclovir, in prevention of *Pneumocystis carinii* infection, 287
- Hyperinflation, in COPD, 367-371
- Hyperkalemia, cyclosporine and, following lung transplantation, 283
- Hyperplasia, gingival, cyclosporine and, following lung transplantation, 282
- smooth muscle, in chronic bronchitis, 391
- Hypertension, cyclosporine and, following lung transplantation, 281
- dyspnea related to, 419-420
- pulmonary, drug abuse as cause of, 153-155
- Hyperthermia, malignant, drug-induced, 184
- Hyperthermic cardiopulmonary bypass, for procurement of donor lungs, 220
- Hypertrichosis, cyclosporine and, following lung transplantation, 282
- Hypnotics, for COPD, 478-479
- Hypomagnesemia, cyclosporine and, following lung transplantation, 282-283
- Hypotension, following double lung transplantation, 232
- Hypoventilation, central, drug-induced, 177-179
- Hypoxemia, in early postoperative management following lung transplantation, differential diagnosis, 266-267
- Hypoxia, tissue, in ARDS, 716-720
- Ibuprofen, for ARDS, 782
- IL-2R, soluble, serial determinations of, in clinical diagnosis of rejection, 274-275
- Immunocompetence, impaired, conditions predisposing to, 56
- diffuse pulmonary infiltrates in, 53-64
- and drug-induced pulmonary disease, 58-59
- and idiopathic interstitial fibrosis, 61-62
- and infection, 59-61
- and pulmonary disease, unusual complications, 62
- and recurrence of underlying pulmonary process, 57-58
- and "unrelated" disease, 62
- Immunosuppression, following heart-lung transplantation, 242
- following lung transplantation, in COPD patients, 551-553
- early postoperative management, 263
- Immunosuppressive agents, in management of bone marrow transplant recipients, pulmonary complications caused by, 321-322
- in management of lung transplant recipients, 279-280
- Infection, ARDS-associated, 576-579
- and chronic allograft rejection, 303-306
- extrapulmonary, as cause of pneumonia in ARDS, 644-645
- as factor in pulmonary sequelae following ARDS, 796-797
- following heart-lung transplantation, 243-244
- following lung transplantation, prevention, 286
- lung, associated with donor lung, 219-220
- in the immunocompromised host, 59-61
- fungal, 60-61
- Inflammation, in chronic bronchitis, 391
- regulation of, cytokines in, 624-626
- Inflation-deflation cycle, of lungs, 674-675
- Inhalational agents, as cause of bronchospasm, 171-172
- Inspiratory muscle training, in COPD, 431-433
- Intermittent negative pressure ventilation, for dyspnea, 436
- Interstitial, anatomy, 658-660
- Iodide, for COPD, 472
- Ipratropium, for COPD, 470-471
- Kidney failure, in ARDS, 582
- bleomycin-induced, and risk of pulmonary toxicity, 5-6
- Kidney function, and fluid balance, in early postoperative management following lung transplantation, 261-262
- Legionella pneumophila*, as cause of bacterial pneumonia following bone marrow transplantation, 324
- Legionella pneumophila* infection, in the immunocompromised host, 59
- Leukemia, pulmonary complications, 57-58
- Liver failure, in ARDS, 582-583
- Lomustine, pulmonary toxicity, 48
- Lung, infection of, in the immunocompromised host, 59-61
- injured, metabolic function of, 726-730
- mechanics of, in ARDS, 673-690. See also *Adult respiratory distress syndrome, lung mechanics.*
- normal, 673-675
- metabolic activity of, 724-726
- pathology, in ARDS, 593-619
- Lung injury, amiodarone-induced, histopathology, 113-114
- azathioprine-induced, 39-40
- bleomycin-induced, 98-99
- busulfan-induced, 35-36
- carbamustine-induced, 45-47
- chlorambucil-induced, 36
- chlorzotocin-induced, 48-49
- cyclophosphamide-induced, 31-35, 101-102
- cytosine arabinoside-induced, 38-39
- drug-induced, antirheumatic agents as cause of, 139-150
- histopathology, 95-117
- lomustine-induced, 48
- melfalan-induced, 36
- 6-mercaptopurine-induced, 39-40
- methotrexate-induced, 36-39, 99-100
- mitomycin-induced, 40-43, 102-103
- neocarzinostatin-induced, 43
- oxygen-induced, 73-86
- biochemical basis of, 73-76. See also *Oxygen toxicity, biochemical basis of.*
- pathology, 78-80
- pharmacologic aspects, 76-78
- physiologic manifestations, 80-82
- procarbazine-induced, 49
- radiation-induced, 65-71
- clinical presentation, 67-69
- radiation fibrosis, 68
- radiation pneumonitis, 67-68
- diagnosis, 69
- histopathology, 66-67
- pathogenesis, 65-67
- potentiation of toxicity, 69
- radiobiology, 65-66
- treatment, 69-70
- semustine-induced, 48
- septic, pathology, 636
- stages, radiographic assessment, 737-743

- teniposide-induced, 49
- Lung transplantation, airway complications following, radiologic assessment, 341-343
 - allograft rejection following, 336-339
 - diagnosis and management, 269-278. See also *Allograft rejection, lung*.
 - applicable assessment, psychosocial, 247-249
 - stress as factor in, 248
 - bronchiolitis obliterans following, radiologic assessment, 339-341
 - for COPD, 547-554
 - donor criteria, 548
 - immunosuppression following, treatment, 551-553
 - patient selection, 547-548
 - procedures, 548-551
 - rejection following, 553
 - donor lung in, and early thoracic infections, 219-220
 - preservation techniques, 223-225
 - procurement of, 220-222
 - donors in, 217-226
 - future directions, 225
 - general maintenance, 217-218
 - selection procedure, 218-219
 - double, 227-233
 - arterial blood gases following, 351
 - clinical experience, 230
 - complications, 230-232
 - for COPD, procedure, 549-550
 - donor selection for, 228
 - hemorrhage following, re-exploration for, 232
 - history, 227-228
 - hypotension following, 232
 - indications, 209
 - modified Bruce protocol following, 356
 - pulmonary function tests following, 350
 - recipients for, 228
 - sepsis following, 232-233
 - 6-minute walk test following, 352-354
 - stage I exercise test following, 356
 - technique, 229-230
 - functional outcome and life satisfaction following, 254-256
 - issue on, 193-358
 - lymphoproliferative disorders following, radiologic assessment, 342, 344
 - postoperative management, 279-290
 - azathioprine, 280
 - cyclosporine, 279-280
 - side effects, 280-283
 - in cystic fibrosis patients, 284-285
 - diaphragmatic paralysis, 288
 - drug interactions, 283-284
 - early, 259-267
 - airway, 265-266
 - anticoagulation, 265
 - antimicrobial therapy, 262-263
 - hemodynamic, 261
 - hypoxemia, 266
 - immunosuppression, 263
 - nutrition, 262
 - renal function and fluid balance, 261-262
 - ventilatory, 263-265
 - in the home, 288-289
 - immunosuppressive agents, 279-280
 - nutritional aspects, 285-286
 - prednisone, 280
 - prevention of lethal infections, 286-287
 - stents in, 287-288
 - preoperative assessment, 207-215
 - formal, 214
 - psychiatric, psychosocial, and rehabilitative aspects, 247-257
 - psychiatric and psychosocial aspects, in postoperative phase, 252-254
 - in preoperative phase, 249-251
 - pulmonary and cardiac changes following, radiologic assessment, 342-345
 - pulmonary nodular disease following, radiologic assessment, 345
 - radiologic assessment following, 333-346
 - recipients of, infectious complications in, 291-308. See also *Allograft recipients, lung, infectious complications in*.
 - in Toronto Lung Transplant Group, arterial blood gases, 351-352
 - long-term functional follow-up of, 347-358
 - modified Bruce protocol, 356
 - mortality data, 348-349
 - pulmonary function tests, 349-350
 - 6-minute walk test, 352-354
 - stage I exercise test, 354-356
 - rehabilitative aspects, in postoperative phase, 254
 - in preoperative phase, 251-252
 - reimplantation response following, radiologic assessment, 333-336
 - selection criteria, 210-214
 - medical, 210-213
 - psychosocial, 213-214
 - single, anesthetic considerations, 196-198
 - arterial blood gases following, 351
 - choice of side in, 196
 - contraindications, 195-196
 - for COPD, procedure, 550-551
 - in emphysema patients, 228
 - harvest for, technique, 196
 - indications, 208-209
 - modified Bruce protocol following, 356
 - pulmonary function tests following, 349-350
 - quantitative perfusion lung scan following, 356
 - 6-minute walk test following, 352
 - stage I exercise test following, 354-355
 - surgical aspects, 195-205
 - technique, 198-203
- Lymphocytes, role in inflammatory process associated with bleomycin-induced lung fibrosis, 26-27
- Lymphoma, following lung transplantation, radiologic assessment, 342
 - pulmonary complications, 57
- Lymphoproliferative disease, as cause of fungal infections in lung transplant recipients, 303
- Macrophages, in ARDS, 624
 - role in inflammatory process associated with bleomycin-induced lung fibrosis, 26
- Magnetic resonance imaging (MRI), in COPD, 414
 - in morphologic diagnosis of drug-induced pulmonary disease, 92-93
- Magnetic resonance spectroscopy, in morphologic diagnosis of drug-induced pulmonary disease, 92-93
- Malnourishment, COPD-related, 435-436
- Malnutrition, as factor in pneumonia, 650
 - following lung transplantation, in cystic fibrosis patients, 284-285
- Marijuana abuse, pulmonary complications caused by, 158-159
- Mediastinitis, in lung allograft recipients, 294-295
- Medical Research Council Dyspnea Scale, modified, 439

- Melphalan, pulmonary toxicity of, 36
- 6-Mercaptopurine, pulmonary toxicity of, 39-40
- Methotrexate, pulmonary toxicity of, 36-39
- and lung injury, 99-100
 - clinical features, 37
 - histopathology, 100-101
 - incidence and mechanisms, 36-37
 - pathology, 38
 - prognosis, 38
 - risk factors, 37
 - and pulmonary disease, 144-145
 - and rheumatoid lung, 110-111
- Methylphenidate, for COPD, 475
- Methylprednisolone, for ARDS, 775-776
- Methylxanthines, for COPD, 366-367
- Mitomycin, as cause of lung injury, histopathology, 103
- pulmonary toxicity of, 40-43
 - and lung injury, 102-103
 - clinical features, 41-43
 - prognosis, 43
 - risk factors, 42
- Mononucleosis syndrome, as cause of fungal infections in lung transplant recipients, 302-303
- Morphine, for dyspnea in COPD, 431
- Mucokinetic agents, for COPD, 472-473
- Mucolytics, for COPD, 473
- Multiple organ failure, in ARDS, 581-591
- complement hypothesis and, 628-629
 - definition, 581
 - epidemiology, 581-583
 - incidence, 582
 - management, 587-588
 - pathogenesis, 584-586
 - prevention, 588-589, 639-641
 - sepsis and, 634-635
- Muscle relaxants, as cause of neuromuscular transmission impairment, 181
- Myasthenia gravis, drug-induced, 181
- Myoneural function, impaired, drug-induced, 180-182
- Myopathies, drug-induced, 182-184
- acute painful, 182
 - chronic painless, 183
- Myotonia, drug-induced, 183-184
- Narcotic abuse, pulmonary complications caused by, 155-156
- Narcotics, for dyspnea in COPD, 431
- Neocarzinostatin, pulmonary toxicity, 43
- Neuroleptic malignant syndrome, 184
- Neuromuscular blockade, drug-induced, treatment, 181-182
- Neuromuscular blocking agents, as cause of bronchospasm, 172
- Neuropathies, drug-induced, 179
- Neutrophils, in ARDS, 621-622, 627-628
- role in inflammatory process associated with bleomycin-induced lung fibrosis, 26
- Nifedipine, for cor pulmonale in COPD, 534-536
- Nitrendipine, for cor pulmonale in COPD, 536
- Nitrofurantoin, as cause of lung injury, 105
- Nitrosoureas, pulmonary toxicity, 45-49
- Nocardiosis, in the immunocompromised host, 59
- Nonsteroidal anti-inflammatory drugs (NSAIDs), for ARDS, 781-782
- as cause of pulmonary disease, 146-147
- Normothermic autoperfusion, for procurement of donor lungs, 220-221
- NSAIDs. See *Nonsteroidal anti-inflammatory drugs*.
- Nuclear scintigraphy, in morphologic diagnosis of drug-induced pulmonary disease, 91-92
- Nutrition, in COPD, assessment, 487-494
- anthropometrics, 490-491
 - body composition, 492
 - body weight, 488-490
 - hepatic secretory proteins, 492-493
 - immunocompetence, 493
 - muscle mass, 491-492
 - muscle physiology, 493-494
 - nitrogen balance, 492
 - significance, 487-488
 - support, 494-502
 - calorie-protein demand, 496-498
 - calorie-protein supply, 498-500
 - clinical trials, 495-496
 - counseling strategies, 498-499
 - substrates and gas-exchange, 500-501
 - in early postoperative management following lung transplantation, 213, 262
 - in prevention of pneumonia, 650
 - repletion of, in COPD patients, 435-436
- Occupations, as factor in COPD, 381-382
- Omentum, radiologic assessment, following lung transplantation, 345
- Organ failure, multiple. See *Multiple organ failure*.
- Oxygen, and bleomycin therapy, pulmonary toxic reactions to, 5
- inspired, in ARDS, 756-757
 - intermediate/antioxidant systems, role in bleomycin-induced lung fibrosis, 22-23
 - presence of, 506
 - supplemental, as factor in pulmonary sequelae following ARDS, 795-796
 - supply and consumption, in ARDS, 715-722
- Oxygen conserving devices, 514-516
- Oxygen-cost diagram, in dyspnea, 438
- Oxygen delivery, in COPD patients, 513-516
- Oxygen system, for COPD patients, 511-513
- Oxygen therapy, for acute respiratory failure in COPD, 508-509
- for COPD, 474-475
 - establishment of baseline blood gases prior to, 508
 - historical perspectives, 505
 - in the home, long-term, for COPD, 505-521
 - cosmetic considerations, 516
 - cost considerations, 516
 - during exercise, 509
 - future of, 517-518
 - goals, 510
 - guidelines, 509-510
 - Medicare reimbursement guidelines, 517-518
 - multicenter trials, 506-508
 - oxygen delivery, 513-516
 - oxygen systems, 511-513
 - portability, 516-517
 - risk factors, 517
 - during sleep, 509
 - pulmonary hemodynamics, 508
- Oxygen toxicity, biochemical basis of, 73-76
- antioxidant systems, 74
 - cytochrome P₄₅₀ system, 76
 - effects of oxidants on cellular lipids, 76
 - effects of oxidants on DNA, 75-76
 - free radical mechanisms, 73-74
 - pathology, 78-80
 - physiologic manifestation of, 80-82

- protein and DNA synthesis, 75
- sulphydryl oxidation, 74-75
- surfactant system, 76
- as cause of lung injury, 73-86
- pharmacologic aspects, 76-78
- Oxygen transport, in ARDS, 719-720
- in COPD, 525-529
- Oxygenation, extracorporeal membrane, in ARDS, 762-765
- mixed venous, in COPD, 525-529
- prone posture in, 767-768
- Oxymatic, for oxygen delivery, 516
- Oxymizer, for oxygen delivery, 515

- Papworth pulmonary preservation solution, composition of, 222
- Paralysis, diaphragmatic, following lung transplantation, 288
- PDO₂, for oxygen delivery, 516
- PEEP. *See Positive end-expiratory pressure.*
- Pendant, for oxygen delivery, 515
- Penicillamine, as cause of bronchiolitis obliterans, 111-112
- as cause of pulmonary disease, 139-142
- Pentoxifylline, for ARDS, 783
- Phlebotomy, for cor pulmonale in COPD, 539-541
- Phycomycosis, in the immunocompromised host, 61
- Pneumocystis carinii* infection, following bone marrow transplantation, 325, 328
- in lung allograft recipients, 299-301
- clinical manifestations, 299-300
- diagnosis, 299
- prevalence, 299
- prevention, 287
- time course, 299
- treatment and outcome, 300-301
- Pneumocystis carinii* pneumonia, in the immunocompromised host, 61
- Pneumonia, bacterial, associated with donor lung, 219-220
- following bone marrow transplantation, 324, 328
- in lung allograft recipients, 293-294
- diagnosis, 293
- pathogenesis, 294
- prevalence, 293
- treatment and outcome, 294
- fungal, following bone marrow transplantation, 325
- interstitial, desquamative, drug-induced, 103-104
- lymphocytic, drug-induced, 105-106
- nosocomial, in ARDS, 641-656
- bacteriology, 648-649
- diagnosis, 645-648
- incidence, 641-642
- and lung injury, 634
- mortality rate, 642
- pathogenesis, 642-645
- prevention, 649-651
- radiographic assessment, 746-747
- as factor in pulmonary sequelae following ARDS, 796-797
- Pneumocystis carinii*, following bone marrow transplantation, 325
- viral, following bone marrow transplantation, 325-326, 328
- Pneumonitis, hypersensitivity, bleomycin-induced, 16-17
- gold salt-induced, 142-143
- interstitial, idiopathic, following bone marrow transplantation, 327
- methotrexate-induced, 99-100, 144-145
- radiation, 67-68
- diagnosis, 69
- Polymyxin B, in prevention of pneumonia, 650
- PortaMate and Omni, for oxygen delivery, 516
- Positive end-expiratory pressure (PEEP), in ARDS, 695-697, 756-757
- cardiovascular effects, 756
- fluctuating, in ARDS, 768-769
- intermittent positive-pressure ventilation with, 703-704
- management, application of, 757
- Posture, effect on dyspnea, 436
- Prednisone, for COPD, 471-472
- in early postoperative management following lung transplantation, 263
- in management of lung allograft rejection, 275
- in management of lung transplant recipients, 280
- Preload, left ventricular, 698-699
- right ventricular, 692-694
- Procarbazine, pulmonary toxicity, 49
- Prostaglandins, for cor pulmonale in COPD, 537
- E_i, for ARDS, 776-778
- in prevention of ARDS and multiple organ failure, 640
- Proteinosis, alveolar, drug-induced, 106-109
- Psychosocial assessment, in lung transplant applicants, 247-249
- Pulmonary artery flush techniques, in procurement of donor lungs, 221-222
- Pulmonary disease, antirheumatic agents as cause of, 139-150
- colchicine-induced, 147
- diffuse, differential diagnosis, in the immunocompromised host, 56
- drug-induced, evaluation, diagnostic imaging techniques, 87-94
- histopathology, 95-117
- in the immunocompromised host, 58-59
- issue on, 1-194
- gold salt-induced, 142-144
- in the immunocompromised host, 55-64
- interstitial, penicillamine-associated, 142
- NSAID-induced, 146-147
- penicillamine-induced, 139-142
- Pulmonary edema, ethchlorvynol abuse as cause of, 158
- following bone marrow transplantation, 326
- heroin abuse as cause of, 155-156
- salicylate-induced, 145-146
- Pulmonary eosinophilia, as cause of lung injury, 104-105
- Pulmonary function testing, for amiodarone pulmonary toxicity, 122-123
- in COPD, 407-410
- following heart-lung transplantation, 273
- in lung transplant recipients, 349-350
- Pulmonary function tests, effect of bleomycin on, 14-16
- Pulmonary heart disease, in COPD, 523-545
- circulatory pathophysiology, 524-529
- treatment, 529-539
- phlebotomy, 539-541
- definition, 523
- Pulmonary hemodynamics, in COPD, 508
- Pulmonary nodular disease, following lung transplantation, radiologic assessment, 345
- Pulmonary rehabilitation, in COPD patients, 447-460, 510-511
- benefits, 448-450, 459
- components, 448
- cost-effectiveness, 450-452
- definition, 455

- Pulmonary rehabilitation (*Continued*)
 limitations, 459
 role of rehabilitation team in, 448
 sequence of, 456-457
 services required for, 457-459
- Pulmonary-renal syndrome, penicillamine-associated, 140-141
- Pulmonary toxicity, amiodarone-induced, clinical aspects, 119-129
 mechanisms, 131-138
 bleomycin-induced, 1-20
 factors influencing, 2-6
 age, 2
 chemotherapeutic agents, 6
 dose, 2-4
 oxygen therapy, 5
 radiation therapy, 4-5
 renal function, 5-6
 route of administration, 6
 incidence, 2-3
 types, 1-17. See also specific types, e.g., *Fibrosis, interstitial, bleomycin-induced.*
 of cytotoxic agents, 31-54
 types, 1-2
- Pulmonary vasculature, in ARDS, 606-612
- Pulmonary vasodilators, for COPD, 476
- Pursed lips breathing, in COPD, 433
- Radiation, and bleomycin therapy, pulmonary toxic reactions to, 4
 as cause of lung injury, 65-71. See also *Lung injury, radiation-induced.*
- Radiography, in ARDS, 737-754
 in assessment of intrathoracic complications of tube placement, 748-752
 in detection of barotrauma, 747-748
 in detection of nosocomial infection, 746-747
 in distinguishing hydrostatic and increased-permeability edema, 745-746
 chest, in drug-induced pulmonary disease, 87-88
 diagnostic, in lung transplantation, 333-346
 morphologic, clinical application, 87-91
 future directions, 92-93
 nuclear scintigraphy for, 91-92
- Radiomimetic agents, as cause of lung injury, histopathology, 95-98
- Radiomimetic injury, definition, 95
- Rehabilitation, following lung transplantation, 251-252, 254
- Reimplantation response, following lung transplantation, 333-336
- Renal function. See *Kidney function.*
- Respiration, effects of theophylline on, 462-463
- Respiratory depression, drug-induced, 177-179
- Respiratory failure, hypoxemic, acute, history, 715-716
- Respiratory muscles, adverse effects of drugs on, 177-189
- Rheumatoid lung, drug-induced, 110-113
- Salicylates, as cause of pulmonary disease, 145-146
- Semustine, pulmonary toxicity, 48
- Sepsis, in ARDS, 576-579, 633-641
 epidemiology, 635-636
 immune factors in, 640
 and lung injury, 634-639
 pathogenesis, 636-637
- predictors of, 637-638
 prognosis, 638-639
 risk factors, 636
 treatment, 773-787
 as cause of multiple organ failure, 634-635
 prevention, preformed antibodies in, 651
- Septicemia, gram-negative, following double lung transplantation, 232-233
- 6-minute walk test, in long-term functional follow-up of lung transplant recipients, 352-354
- Skin lesions, precancerous, cyclosporine and, following lung transplantation, 283
- Sleep, oxygen therapy during, in COPD patients, 509
- Smoking, cigarette, as factor in COPD, 366, 380, 381
 as factor in pulmonary sequelae following ARDS, 795
- Socioeconomic status, as factor in COPD, 380-381
- Stage I exercise test, in lung transplant recipients, 354-356
- Stents, in management of anastomotic complications following lung transplantation, 287-288
- Steroids, as cause of neuromuscular transmission impairment, 181
- Stress, in lung transplant patients, 248
- Strongyloides stercoralis* infection, in the immunocompromised host, 61
- Substance abuse, pulmonary reactions, 151-162. See also *Drug abuse.*
- Surfactant, for ARDS, 778-780
- β -Sympathomimetics, for COPD, 465-469
 cardiovascular effects, 468
 dosages, 468-469
 respiratory effects, 466-467
 history, 465-466
 pharmacology, 466
 theophylline and, for COPD, 465
- β_2 -Sympathomimetics, 425-429
- Teniposide, pulmonary toxicity, 49
- Theophylline, β_2 -adrenoceptor agonists and, for COPD, 467-468
 for COPD, 426-429, 461-465, 475
 cardiovascular effects, 463
 preparation and dosages, 463-465
 respiratory effects, 462-463
 β -sympathomimetics and, 465
 for cor pulmonale in COPD, 530
 for dyspnea, 426-429
 history, 461
- Thoracic imaging, in COPD, 410-414
- Thoracic infections, associated with donor lung, 219-220
- Toronto Lung Transplant Group, patient follow-up in, 347-358
- Toxicity, pulmonary. See *Pulmonary toxicity.*
- Toxoplasmosis, in the immunocompromised host, 61
- Transplantation, bone marrow, pulmonary complications following, 58, 321-332. See also *Bone marrow transplantation, pulmonary complications following.*
 heart-lung. See *Heart-lung transplantation.*
 lung. See *Lung transplantation.*
- Transtacheal catheters, for oxygen delivery, 514-515
- Tremor, drug-induced, 184
- Trimethoprim-sulfamethoxazole, for prevention of *Pneumocystis carinii* infection, following lung transplantation, 287, 553
- Tube malposition, in ARDS, radiographic assessment, 748-752

- University of Pittsburgh experience, in pulmonary transplantation, 291-308
- University of Wisconsin solution, composition of, 224
- Urapidil, for cor pulmonale in COPD, 536-537
- Vasculitis, drug-induced, 109-110
- Vasodilators, for cor pulmonale in COPD, 532-537
- pulmonary, for COPD, 476
- Ventilation, effects, on left ventricular function, 698-705
- on right ventricular function, 691-698
- high-frequency, in ARDS, 765-767
- intermittent negative pressure. *See Intermittent negative pressure ventilation.*
- intermittent positive pressure, 702-705
- inverse ratio, in ARDS, 760-762
- mechanical, in ARDS, 755-772
- goals, 755-756
- conventional, in ARDS, 758-759
- pressure-controlled, lung mechanics measurement in, 684
- Ventricle, left, afterload, 702
- effect of ventilation on, 698-705
- function of, in ARDS, 706-709
- preload, 698-699
- right, afterload, 694-698
- effect of ventilation on, 691-698
- function of, in ARDS, 705-706
- preload, 692-694
- Vinblastine, pulmonary toxicity, 43-45
- Vinca alkaloids, pulmonary toxicity, 43-45
- Vindesine, pulmonary toxicity, 43-45
- von Willebrand factor, role in endothelial cell injury, 724, 725
- Water, for COPD, 472
- Weight, as factor in undernutrition in COPD, 488-490
- gain in, excessive, following lung transplantation, 286